On December 11, 2017, President Trump signed Space Policy Directive 1, fundamentally redirecting NASA's mission architecture toward lunar exploration as a prerequisite for eventual human Mars missions. The directive tasked the space agency with establishing a timeline for returning humans to the Moon and repositioning the International Space Station as a hybrid government-commercial facility rather than a purely government-operated platform. The mechanism was a presidential directive rather than legislation, granting the administration significant latitude in reshaping space agency priorities without requiring congressional approval, though subsequent budget allocations required appropriations from Congress.

The directive's immediate effects rippled through NASA's operational and budgetary structures. Space exploration contractors, lunar mission planners, and ISS management teams faced significant reprioritization of resources. The Agency's advanced deep space exploration programs, including some Earth science and fundamental research initiatives, experienced funding pressure as budgets shifted toward Artemis lunar missions. Commercial space companies gained expanded roles in ISS operations, fundamentally altering the station's governance model from purely governmental to a public-private hybrid. Scientists and engineers working on non-lunar programs confronted resource constraints and mission delays.

This 2017 directive represents an early instance of a broader pattern evident in subsequent Trump administration actions targeting the scientific establishment. The later dissolution of the President's Council of Advisors on Science and Technology and the termination of National Science Board members both reflect a consistent approach of reducing institutionalized scientific input into federal policymaking. Where Space Policy Directive 1 redirected scientific resources toward specific objectives, these later actions systematically diminished the advisory capacity of scientific institutions themselves, suggesting an administration model that prefers directive implementation over collaborative scientific governance.

The directive has remained substantially active, with NASA continuing lunar program development under the Artemis framework established by this directive. No significant legal challenges emerged, though congressional appropriations committees have periodically questioned budget allocations and timelines. Reversal would require either a new presidential directive deprioritizing lunar missions or congressional action reallocating space exploration funding toward alternative scientific priorities.